Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sildenafil citrate (open label) Clear all
Completed Phase 4 Interventional Results available

Effect of Testosterone in Men With Erectile Dysfunction

NCT00512707
View directory record Official record
Conditions
Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions
Sildenafil citrate (open label), Testosterone gel, Placebo gel
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Sep 30, 2026, 1:38 AM EDT
Terminated Not applicable Interventional Results available

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

NCT00955929
View directory record Official record
Conditions
Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
Interventions
Placebo QHS and sildenafil and questionnaires, Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

NCT00142506
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
sildenafil citrate and questionaires, placebo tablets and questionaires
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects

NCT00866463
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional Results available

Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

NCT01168908
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Sildenafil
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 2 Interventional

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

NCT00746967
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions
sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
82
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 4 Interventional

Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire

NCT00147628
View directory record Official record
Conditions
Impotence
Interventions
sildenafil citrate, placebo for sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
20
States / cities
Huntsville, Alabama • San Diego, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Early Phase 1 Interventional

Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction

NCT03229512
View directory record Official record
Conditions
Hand Foot Skin Reaction
Interventions
Sildenafil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional

A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis

NCT01954524
View directory record Official record
Conditions
Cirrhosis
Interventions
IV bolus injection of Sildenafil
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 4 Interventional Results available

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

NCT00323297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Bosentan, Placebo, Sildenafil Citrate
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet

NCT00950404
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Viagra 50 mg tablet, Formulation B ODT tablet 50 mg, Formulation C ODT tablet 50 mg, Formulation D ODT tablet 50 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional

Cerebrovascular Reactivity in American Football Players

NCT03417492
View directory record Official record
Conditions
Traumatic Brain Injury, Mild Traumatic Brain Injury, Post-Concussion Syndrome
Interventions
Sildenafil Citrate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 30, 2026, 1:38 AM EDT
Terminated Phase 3 Interventional Results available

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

NCT00796510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Sitaxsentan and Sildenafil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Sep 30, 2026, 1:38 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure

NCT00793338
View directory record Official record
Conditions
Heart Failure
Interventions
Sildenafil
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)

NCT02114775
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Growth Hormone, Sildenafil, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations

NCT01290484
View directory record Official record
Conditions
Lymphangioma
Interventions
Sildenafil
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

NCT01375699
View directory record Official record
Conditions
Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Sarcoma, Gynecologic Cancer
Interventions
Doxorubicin, Sildenafil
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Sep 30, 2026, 1:38 AM EDT
Not yet recruiting Phase 1 Interventional

Vaginal Sildenafil for Primary Dysmenorrhea

NCT07508358
View directory record Official record
Conditions
Dysmenorrhea, Menstrual Pain, Endometriosis, Uterine Fibroid
Interventions
Sildenafil citrate vaginal suppository
Drug
Lead sponsor
Kevin Hellman
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 1:38 AM EDT
Completed Phase 4 Interventional

An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)

NCT00194909
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
sildenafil (Viagra)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Sep 30, 2026, 1:38 AM EDT
Terminated Phase 4 Interventional Results available

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

NCT00430716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 30, 2026, 1:38 AM EDT